Expert Discusses Docetaxel Versus Abiraterone in Hormone-Sensitive Prostate Cancer
William K. Oh, MD, discusses treatment with abiraterone versus docetaxel in patients with prostate cancer, other remaining questions in the field, and what role immunotherapy is poised to play.
Source: OncLive